Gilead Sciences | GILD - Capital Ordinário

Preço das Ações
130.45
Mudança Diária
-0.24 -0.18%
Mensal
-1.84%
Anual
22.21%
Q2 Previsão
126.98




Capital Ordinário Alterar Data
AbbVie USD 1.77B 1.75B 2025-06
Agios Pharmaceuticals USD 59.34M 892K 2026-03
ALKERMES USD 166.46M 855K 2026-03
Alnylam Pharmaceuticals USD 133.44M 1.07M 2026-03
Amgen USD 540M 1000K 2026-03
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Coherus Biosciences USD 121.16M 4.92M 2025-12
Eli Lilly USD 943.5M 3.33M 2026-03
Gilead Sciences USD 1.24B 1000K 2026-03
GlaxoSmithKline GBP 4.05B 20.6M 2026-03
Glaxosmithkline GBP 4.08B 49.43M 2025-12
Incyte USD 199.95M 1.49M 2026-03
J&J USD 2.41B 1.74M 2025-12
Merck USD 2.47B 12.72M 2025-12
Moderna USD 391M 2M 2025-09
Neurocrine Biosciences USD 100.6M 500K 2026-03
Novartis USD 1.91B 60K 2026-03
Pfizer USD 5.7B 13M 2026-03
PTC Therapeutics USD 81.47M 1.54M 2025-12
Puma Biotechnology USD 5K 0 2024-06
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Sanofi EUR 1.21B 8.25M 2026-03
Sarepta Therapeutics USD 105.57M 607K 2026-03
United Therapeutics USD 42.16M 1.49M 2026-03
Vertex Pharmaceuticals USD 254.2M 200K 2026-03